Remedent, Inc.

As of December 31, 2020, Remedent, Inc. carries a market capitalization of 3.00M, placing it among publicly traded companies globally. Its enterprise value stands at 3.00M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2020, Remedent, Inc. has 20.00M shares outstanding.

These figures are as of December 31, 2020. The price-to-sales ratio is 2.66, and the price-to-book ratio stands at 0.66.

These figures are as of December 31, 2020. The EV/Sales ratio of 2.66 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.00M versus a market cap of 3.00M, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2020, Remedent, Inc. maintains a current ratio of 0.24, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.12, indicating conservative leverage, while an interest coverage ratio of -6.04 demonstrates limited ability to service its debt obligations.

Over the twelve months ended December 31, 2020, Remedent, Inc. posted a negative return on equity (ROE) of -5.49, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.39, reflecting losses generated across the asset base. The company generates approximately 376,275.67 in revenue per employee across its workforce of 3.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.45 indicates how many times Remedent, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2020, Remedent, Inc. recorded 3,048.00 in income tax expense. The company reported a pretax loss of -244,985.00 and -259,380.00 in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on September 9, 2026, Remedent, Inc.'s stock has declined approximately 91.09% over the past 52 weeks. The 50-day moving average sits at 0.04, while the 200-day moving average is 0.13.

Over the twelve months ended December 31, 2020, Remedent, Inc. generated 1.13M in revenue and converted that into -259,380.00 in net income, yielding earnings per share of -0.01. EBITDA reached -65,537.00, while operating income came in at -106,698.00.

As of December 31, 2020, Remedent, Inc. holds 83,296.00 in cash and equivalents against 5,455.00 in total debt, resulting in a net debt position of -83,296.00. Total book value stands at 4.56M, with working capital of -2.21M providing operational flexibility.

Remedent, Inc. produced 250,562.00 in operating cash flow over the twelve months ended December 31, 2020.

Over the twelve months ended December 31, 2020, Remedent, Inc. posted a gross margin of 65.38, reflecting its pricing power and cost economics. The operating margin of -9.45 and net profit margin of -22.98 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2020. Free cash flow yield stands at 8.35, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt.

Remedent, Inc.'s most recent stock split took place on June 7, 2005 with a 20:1 split ratio.

As of December 31, 2020, Remedent, Inc. has an Altman Z-Score of -3.05, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.